DaVita Inc. (NYSE:DVA) Shares Sold by GHP Investment Advisors Inc.

GHP Investment Advisors Inc. cut its holdings in shares of DaVita Inc. (NYSE:DVA) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 44,083 shares of the company’s stock after selling 1,642 shares during the period. GHP Investment Advisors Inc. owned 0.05% of DaVita worth $6,593,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Transcendent Capital Group LLC purchased a new stake in shares of DaVita during the third quarter worth about $25,000. Blue Trust Inc. boosted its stake in DaVita by 56.4% in the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after purchasing an additional 119 shares in the last quarter. Quarry LP acquired a new position in DaVita during the 3rd quarter valued at approximately $60,000. Versant Capital Management Inc raised its holdings in shares of DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after buying an additional 169 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in shares of DaVita during the third quarter worth $97,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Trading Down 2.8 %

Shares of DaVita stock opened at $171.96 on Friday. DaVita Inc. has a 1 year low of $108.76 and a 1 year high of $179.60. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The stock has a market cap of $14.10 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 0.86 and a beta of 0.93. The firm has a fifty day moving average price of $160.45 and a 200 day moving average price of $156.11.

Wall Street Analyst Weigh In

Separately, Barclays upped their target price on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, DaVita presently has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.